Webinar Alert! Building Robust Potency Assays with In-Cell Western Assay Protein Expression Readouts Register Today!

Multiplex In Situ Hybridization (ISH) for Assessing Transgene Expression in GLP-Compliant Programs

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES.

Multiplex In Situ Hybridization (ISH) for Assessing Transgene Expression in GLP-Compliant Programs

Multiplex ISH for Transgene Expression Analysis in GLP Programs

CELL & GENE | RNA | BIOLOGICS

Applying proven intelligence in pathology is a requirement for accelerating the development of advanced therapeutics and complex biologics. Accurately mapping transgene expression and biodistribution within a tissue’s morphological context provides definitive data for IND-enabling toxicology packages. Multiplex in situ hybridization (ISH) offers a precise method for visualizing RNA targets directly within tissue sections, moving beyond the limitations of bulk sample analysis.

A digital rendering of a DNA double helix on a dark blue background with floating particles.

Frequently Asked Questions

    What is multiplex ISH and why is it used in preclinical gene therapy studies?

    Multiplex ISH facilitates the simultaneous detection of multiple RNA targets within a single tissue section. This technique is applied in gene therapy programs to provide spatial context for transgene expression, colocalizing it with specific cell-type markers and immune response indicators.

    Can multiplex ISH be performed under GLP conditions?

    Yes. When the methodology is properly developed, qualified, and executed with rigorous documentation and quality assurance oversight, multiplex ISH generates robust, reproducible data suitable for inclusion in IND-enabling toxicology studies.

    How does multiplex ISH differ from immunohistochemistry (IHC)?

    ISH directly detects target RNA sequences, confirming transcription of the transgene. IHC detects the resulting protein product. Employing both techniques provides a more complete assessment of the biological cascade from transcription to translation.

A stylized, 3D rendering of a DNA double helix in light blue and white, set against a soft-focus, light gray background.

Establishing Spatial Context in Biodistribution

Quantitative PCR and bulk RNA sequencing are effective for measuring overall transgene levels in a given tissue, but they lack spatial resolution. These methods cannot distinguish between low-level expression across many cells versus high-level expression in a small, specific cell population.

For AAV-based vectors and other targeted delivery systems, understanding precisely which cells are transcribing the payload is fundamental to evaluating both efficacy and potential toxicity. Multiplex ISH preserves the architectural integrity of the tissue, allowing for the direct visualization of transgene RNA. This allows investigators to confirm on-target cellular tropism and identify any off-target expression that could inform unexpected safety signals.

Correlating Expression with Pathological Findings

Unintended transgene expression in non-target tissues can be a driver of adverse events. Preclinical safety evaluations have demonstrated that certain immune-mediated toxicities can be correlated with specific patterns of transgene expression (PMID: 37033976).

By using multiplex ISH to co-localize transgene RNA with markers for immune cell infiltration or cellular stress, a clearer picture of the biological mechanism behind a potential toxicity can be constructed. This level of detail is often required to de-risk a program before human trials. This approach is particularly informative in preclinical models where selecting a species with an immune system that mirrors the human response is a key component of a data-driven preclinical strategy.

A marketing flyer for Franklin Biolabs detailing their immunogenicity services, including various assays and support for cell and gene therapy clinical trials.

A scientist in a sterile laboratory setting uses a multichannel pipette to transfer pink liquid into a multi-well plate for a high-throughput experiment.

A Tailored Preclinical Strategy

A standard testing template does not exist for gene therapies. A data-driven preclinical strategy must be tailored to the specific vector, payload, and target indication. Incorporating advanced histological techniques like multiplex ISH into GLP-compliant toxicology programs provides the high-resolution data needed to make confident decisions and assemble a robust regulatory submission.

Related Services

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities